We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+13.95%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.96B
AUM Growth
-$393M
Cap. Flow
-$554M
Cap. Flow %
-28.28%
Top 10 Hldgs %
32.05%
Holding
103
New
18
Increased
14
Reduced
37
Closed
22

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$49.4M
2
HUM icon
Humana
HUM
+$46.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$26.7M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$26.1M
5
ORKA
Oruka Therapeutics
ORKA
+$24.6M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$61M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$53.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$50.4M
4
AVTR icon
Avantor
AVTR
+$45.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$45.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
76
Instil Bio
TIL
$49.4M
$1.96M 0.1%
+29,100
New +$685K
PRLD icon
77
Prelude Therapeutics
PRLD
$370M
$1.84M 0.09%
+890,000
New +$4.12M
KPTI icon
78
Karyopharm Therapeutics
KPTI
$161M
$1.68M 0.09%
134,567
– –
HYPR icon
79
Hyperfine
HYPR
$90.9M
$1.28M 0.07%
1,188,178
– –
BLUE
80
DELISTED
bluebird bio
BLUE
$847K 0.04%
+81,557
New +$1.36M
CMAX
81
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$36K ﹤0.01%
21,200
– –
ACIU icon
82
AC Immune
ACIU
$236M
– –
-825,000
Closed -$3.29M
ALNY icon
83
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-222,000
Closed -$53.9M
AZN icon
84
AstraZeneca
AZN
$267B
– –
-102,500
Closed -$16M
CI icon
85
Cigna
CI
$79.6B
– –
-184,500
Closed -$61M
COLL icon
86
Collegium Pharmaceutical
COLL
$1.16B
– –
-117,000
Closed -$3.77M
CRBP icon
87
Corbus Pharmaceuticals
CRBP
$168M
– –
-215,600
Closed -$9.76M
GILD icon
88
Gilead Sciences
GILD
$167B
– –
-255,000
Closed -$17.5M
IMTX icon
89
Immatics
IMTX
$1.19B
– –
-393,100
Closed -$4.57M
IONS icon
90
Ionis Pharmaceuticals
IONS
$9.14B
– –
-93,000
Closed -$4.43M
JSPR icon
91
Jasper Therapeutics
JSPR
$21.1M
– –
-782,000
Closed -$17.8M
LEGN icon
92
Legend Biotech
LEGN
$3.68B
– –
-398,000
Closed -$17.6M
LNTH icon
93
Lantheus
LNTH
$6.68B
– –
-290,000
Closed -$23.3M
MRK icon
94
Merck
MRK
$326B
– –
-325,000
Closed -$40.2M
NTLA icon
95
Intellia Therapeutics
NTLA
$1.52B
– –
-170,000
Closed -$3.8M
NUVB.WS
96
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-12,136
Closed -$1.94K
PATH icon
97
UiPath
PATH
$6.32B
– –
-362,000
Closed -$4.59M
PCVX icon
98
Vaxcyte
PCVX
$7.88B
– –
-284,000
Closed -$21.4M
REGN icon
99
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-48,000
Closed -$50.4M
SYRE icon
100
Spyre Therapeutics
SYRE
$8.68B
– –
-195,000
Closed -$4.58M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2024 Portfolio in Review

As of Q3 2024, Avidity Partners Management held 103 positions worth $1.96B, down 17% from $2.35B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Avidity Partners Management withdrew a net $554M in Q3 2024, closing 22 positions and reducing 37 holdings. Its most notable exit was Cigna, an estimated $61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in UnitedHealth worth $51.1M.

  • Avidity Partners Management's largest Q3 2024 buy was UnitedHealth: 87,400 shares worth $51.1M.
  • Avidity Partners Management added most to Oruka Therapeutics in Q3 2024, an estimated $24.6M increase.
  • Avidity Partners Management's biggest Q3 2024 reduction was Avantor, cutting an estimated $45.4M.
  • Avidity Partners Management fully exited Cigna in Q3 2024, selling an estimated $61M.
  • Avidity Partners Management's ten largest holdings make up 32% of its $1.96B portfolio in Q3 2024.
  • Avidity Partners Management opened 18 new positions and closed 22 in Q3 2024.
  • Avidity Partners Management's portfolio value fell 17% quarter-over-quarter to $1.96B.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.